Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

On January 5, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference (Press release, Revolution Medicines, JAN 5, 2021, View Source [SID1234575007]). The conference, which will take place January 11-14, 2021, is being conducted with a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a centerpiece of the update, Dr. Goldsmith will announce the entry of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development and will discuss the profiles of these development candidates and next steps for advancing them. Dr. Goldsmith will also provide an update on the company’s three RAS Companion Inhibitors, including RMC-4630 (SHP2 inhibitor), RMC-5552 (mTORC1-selective inhibitor), and a new member, RMC-5845 (SOS1-selective inhibitor).

Details of Revolution Medicines’ presentation are as follows:

39th Annual J.P. Morgan Healthcare Conference
Conference Date: January 11-14, 2021
Presentation Time/Date: 5:20 p.m. Eastern on Tuesday, January 12, 2021
Format: Virtual conference; webcast available
To access the live webcast of the presentation, please visit the "Events & Presentations" page within the Investors section of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines’ website for at least 14 days following the conference.